Marker Therapeutics, Inc. (MRKR)
MRKR moved a median of -0.23% 30 minutes after news, and -2.09% by the close. How MRKR actually reacts to news — the realized, point-in-time move the market made, measured across 120 labeled events over the last three years with zero look-ahead.
MRKR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 40% | 111 |
| 30-min | -0.23% | 39% | 117 |
| 60-min | -0.12% | 42% | 118 |
| to close | -2.09% | 33% | 118 |
| Middle 50% of MRKR reactions | -2.02% to +0.91% |
|---|---|
| Median reaction (30-min) | -0.23% |
| Measured reactions | 120 |
Half of all Marker Therapeutics, Inc. news events land between -2.02% and +0.91% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when MRKR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MRKR's baseline. Nothing else.
Recent MRKR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies | Press release | GlobeNewswire | +0.00% | +3.39% | |
| Form 10-Q Marker Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.85% | -1.70% | |
| Form 10-Q Marker Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.70% | -2.11% | |
| Form 8-K Marker Therapeutics, For: May 01 | SEC filing · Form 8-K | SEC EDGAR | -1.24% | -5.03% | |
| Form ARS Marker Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +0.00% | |
| Form DEF 14A Marker Therapeutics, For: May 01 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +0.00% | |
| Form DEFA14A Marker Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K Marker Therapeutics, For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | +1.12% | -1.49% | |
| Form 10-K Marker Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.12% | -1.49% | |
| Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results | Press release | GlobeNewswire | +1.12% | -1.49% | |
| Form PRE 14A Marker Therapeutics, For: May 01 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -2.84% | |
| Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | +0.00% | +3.45% | |
| Form 8-K Marker Therapeutics, For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | +2.35% | +3.33% | |
| Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology | Press release | GlobeNewswire | +0.47% | -12.62% | |
| Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer | Press release | GlobeNewswire | +1.23% | +9.82% | |
| Form 8-K Marker Therapeutics, For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | -3.33% | +2.56% | |
| Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | -3.33% | +2.56% | |
| Form 8-K Marker Therapeutics, For: Oct 31 | SEC filing · Form 8-K | SEC EDGAR | +4.09% | +1.90% | |
| Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors | Press release | GlobeNewswire | +4.09% | +1.90% | |
| Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting | Press release | GlobeNewswire | -0.09% | -2.60% | |
| Form 8-K Marker Therapeutics, For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +8.00% | |
| Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program | Press release | GlobeNewswire | +0.00% | +8.00% | |
| Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | -9.40% | -1.53% | |
| Form 8-K Marker Therapeutics, For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | +0.73% | -27.01% | |
| Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma | Press release | GlobeNewswire | +0.73% | -27.01% | |
| Form 10-Q Marker Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.31% | -4.54% | |
| Form 8-K Marker Therapeutics, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -3.10% | +0.00% | |
| Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference | Press release | GlobeNewswire | -1.06% | -4.78% | |
| Form 8-K Marker Therapeutics, For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | -5.39% | -10.18% | |
| Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma | Press release | GlobeNewswire | -5.39% | -10.18% | |
| Form 8-K Marker Therapeutics, For: Jun 06 | SEC filing · Form 8-K | SEC EDGAR | -3.45% | -2.87% | |
| Form 8-K Marker Therapeutics, For: May 20 | SEC filing · Form 8-K | SEC EDGAR | -3.48% | -0.87% | |
| Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma | Press release | GlobeNewswire | -3.48% | -0.87% | |
| Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies | Press release | GlobeNewswire | -1.75% | -0.88% | |
| Form 10-Q Marker Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.83% | -3.48% | |
| Form ARS Marker Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -2.34% | |
| Form DEF 14A Marker Therapeutics, For: Jun 06 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -2.34% | |
| Form DEFA14A Marker Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -2.34% | |
| Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference | Press release | GlobeNewswire | -0.84% | -4.20% | |
| Form 10-K Marker Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.40% | -0.81% | |
| Form 8-K Marker Therapeutics, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -0.40% | -0.81% | |
| Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results | Press release | GlobeNewswire | -0.40% | -0.81% | |
| Form 8-K Marker Therapeutics, For: Mar 21 | SEC filing · Form 8-K | SEC EDGAR | -2.88% | -7.30% | |
| Form 8-K/A Marker Therapeutics, For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | -0.03% | +21.85% | |
| Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference | Press release | GlobeNewswire | — | -3.21% | |
| Form 8-K Marker Therapeutics, For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +2.56% | +4.49% | |
| Form DEF 14A Marker Therapeutics, For: Mar 21 | SEC filing · Form DEF | SEC EDGAR | +1.05% | +6.32% | |
| Form DEFA14A Marker Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +1.05% | +6.32% | |
| Form 8-K Marker Therapeutics, For: Jan 24 | SEC filing · Form 8-K | SEC EDGAR | -1.05% | -3.16% | |
| Form EFFECT Marker Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -18.65% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MRKR section they belong to.
Where else MRKR is measured.
MRKR earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CARL ZEISS MEDI UNSP/ADR (CZMWY) | 120 | -0.21% | 21% |
| HEMP NATURALS INC (HPMM) | 120 | 0.00% | 37% |
| ChromaDex Corporation (CDXC) | 118 | +0.80% | 61% |
| ADHERA THERAPEUTICS INC (ATRX) | 117 | 0.00% | 23% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Marker Therapeutics, Inc.'s median reaction calculated?
Every labeled MRKR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 120 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of MRKR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MRKR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.